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Summary
Familial Mediterranean fever (FMF) is a recessively in-
herited disorder that is common in patients of Armenian
ancestry. To date, its diagnosis, which can be made only
retrospectively, is one of exclusion, based entirely on
nonspecific clinical signs that result from serosal inflam-
mation and that may lead to unnecessary surgery. Renal
amyloidosis, prevented by colchicine, is the most severe
complication of FMF, a disorder associated with mu-
tations in the MEFV gene. To evaluate the diagnostic
and prognostic value of MEFV-gene analysis, we inves-
tigated 90 Armenian FMF patients from 77 unrelated
families that were not selected through genetic-linkage
analysis. Eight mutations, one of which (R408Q) is new,
were found to account for 93% of the 163 independent
FMF alleles, with both FMF alleles identified in 89% of
the patients. In several instances, family studies provided
molecular evidence for pseudodominant transmission
and incomplete penetrance of the disease phenotype.
The M694V homozygous genotype was found to be as-
sociated with a higher prevalence of renal amyloidosis
and arthritis, compared with other genotypes (P 
and , respectively). The demonstration.0002 P  .006
of both the diagnostic and prognostic value of MEFV
analysis and particular modes of inheritance should lead
to newways for management of FMF—including genetic
counseling and therapeutic decisions in affected families.
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Introduction
Familial Mediterranean fever (FMF) is an autosomal re-
cessive condition (MIM 249100) that primarily affects
populations surrounding the Mediterranean basin, the
disease being restricted essentially to Armenian, Se-
phardic Jewish, Turkish, and Arab populations (Sohar
et al. 1967). The frequency of heterozygotes, as deduced
from the prevalence of the disease, is extremely high in
those populations, reaching 1:7 among Armenians (Rog-
ers et al. 1989). This disease is characterized by recurrent
episodes of fever and serosal inflammation manifested
by sterile peritonitis, arthritis, and/or pleurisy, sometimes
associated with erysipelas-like erythema. The major
complication of FMF is amyloidosis, mainly renal, which
develops over years and progresses to terminal renal fail-
ure (Sohar et al. 1967).
Given the absence of pathognomonic clinical symp-
toms and of any specific biochemical abnormality, the
diagnosis of FMF is, at present, one of exclusion; it can
be made only retrospectively, and is based entirely on
clinical criteria (Livneh et al. 1997). It is, however, of
prime importance to ascertain this diagnosis, for the fol-
lowing reasons. First, the symptomatology of FMF may
mimic that of other affections—such as acute peritonitis,
appendicitis, cholecystitis, or arthritis—thereby leading
to unnecessary exploratory surgery (Sohar et al. 1967).
Second, an effective therapy is available: daily and life-
long administration of colchicine not only reduces the
frequency and severity of attacks (Dinarello et al. 1974;
Zemer et al. 1974) but also prevents amyloidosis and
transplantation for renal failure (Zemer et al. 1986).
Furthermore, the rare observation of renal amyloidosis
as the first and sometimes only manifestation of the dis-
ease (Blum et al. 1962; Sohar et al. 1967; Saatci et al.
1997) emphasizes these diagnostic difficulties and raises
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questions with regard to the value of developing pre-
symptomatic diagnostic tests for use in FMF families.
Recently, a candidate gene for FMF (designated
“MEFV”), located on the short arm of chromosome 16
(Pras et al. 1992; French FMF Consortium 1996; Levy
et al. 1996), has been identified independently by two
consortia following a positional cloning approach
(French FMF Consortium 1997; International FMF
Consortium 1997). This gene, which spans ∼15 kb of
the 16p13.3 region, is composed of 10 coding exons.
The 3.7-kb MEFV transcript expressed in polynuclear
leukocytes predicts a protein that has been named both
“marenostrin” (French FMF Consortium 1997) and
“pyrin” (International FMF Consortium 1997) and that
consists of 781 residues. Although the function of the
marenostrin/pyrin protein is unknown, several lines of
evidence suggest a possible role in the regulation of in-
flammation (French FMF Consortium 1997; Interna-
tional FMF Consortium 1997). In these first studies
(French FMF Consortium 1997; International FMF
Consortium 1997), four conservative missense muta-
tions (i.e., M680I, M694V, M694I, and V726A), which
are clustered in exon 10 and are associated with ances-
tral haplotypes, were recovered exclusively on carrier
chromosomes, thereby suggesting that the isolated gene
was involved in FMF, a hypothesis further supported by
the recent description of nonfounder MEFV mutations
(Bernot et al. 1998). However, no unambiguous muta-
tions—such as nonsense, frameshift, or splice muta-
tions—have been described thus far; in addition, to date,
there are no available in vitro assays or animal models
by which to investigate the mutations recently identified
in humans.
The identification of the MEFV gene prompted us to
investigate a large cohort of independent Armenian pa-
tients, with the following aims: (i) to evaluate the interest
of MEFV gene analysis to establish a diagnosis of FMF,
(ii) to determine whether the clinical severity of the dis-
ease phenotype correlates with the nature of the muta-
tion, and (iii) to determine whether such molecular in-
vestigations both lead to new ways of managing this
disease and further confirm the involvement of the
MEFV gene in FMF.
Patients and Methods
Patients
We investigated 90 patients (age 4–68 years [mean
28.8 years]; male:female ratio 1.2:1.0) from 77 unrelated
FMF families originating from Armenia, representing a
total of 163 independent alleles. Of these 77 families,
16 were living in France; the remaining 61 families (70
patients) were living in Armenia. The diagnosis of FMF
was made according to established clinical criteria (Liv-
neh et al. 1997). None of the families were selected
through genetic-linkage analyses using MEFV-gene
markers. A parent-to-offspring transmission of the dis-
ease phenotype was documented in three families.
Clinical features prior to onset of colchicine therapy
(renal amyloidosis, arthritis, fever, peritonitis, pleurisy,
erysipelas-like rash, and diarrhea) were recorded on a
standardized form. Since colchicine was not easily avail-
able in Armenia, all but one of the patients living in that
country did not have access to daily administration of
colchicine. Informed consent was obtained from all pa-
tients or their parents.
Mutation Analysis
Genomic DNA was isolated from peripheral leuko-
cytes, by standard procedures. Different methods were
used to screen for MEFV mutations, according to the
strategy described in figure 1a. The M694V and V726A
mutations (French FMF Consortium 1997; International
FMF Consortium 1997) were screened for by HphI and
AluI digestions, respectively, performed on PCR prod-
ucts generated by primers pM694V-f (5′-AGAAT-
GGCTACTGGGTGGAGAT-3′) and p10A-r (5′-AGAG-
AAAGAGCAGCTGGCGAATGTAT-3′). The E148Q
mutation (Bernot et al. 1998) was screened for by BsrI
digestion of PCR products generated by primers p2-f (5′-
CCGCAGCGTCCAGCTCCCTG-3′) and pE148Q-r (5′-
GCTTCCTCGACAGCCCCCTCCCGGACT-3′). The
pM694V-f and pE148Q-r primers are mismatched prim-
ers: the pM694V-f primer abolishes the HphI restriction
site that is located 9 bp upstream from the M694V mu-
tation site that creates a HphI restriction site, whereas
the pE148Q-r primer introduces a BsrI restriction site
in the presence of the E148Q substitution.
Denaturing gradient gel electrophoreses (DGGE) of
PCR-amplified products of exons 5 and 10 were per-
formed within the framework of an exhaustive scanning
approach designed to screen all the MEFV coding exons
and their flanking intronic sequences (Cazeneuve et al.
1998). These experiments were performed to analyze
both the major part of exon 10 (fragment 10A, con-
sisting of 212 nucleotides surrounding the four clustered
mutations [i.e., M680I, M694V, M694I, and V726A],
and fragment 10B, consisting of 185 nucleotides allow-
ing screening for mutations in the 3′ end of exon 10)
and the entire exon 5 together with flanking intronic
sequences. The DGGE conditions were determined by
means of the MELT87 and SQHTX programs, kindly
provided by L. Lerman. The primer sets used to am-
plify fragment 10A, fragment 10B, and exon 5 were
p10A-f (5′-[GC]40GCATGGATCCTGGGAGCCTG-3
′)
and p10A-r, p10B-f (5′-[GC]50CGTGGACTACAGA-
GTTGGAAGC-3′) and p10B-r (5′-ATACAAGGCCAG-
AAGCAGG-3′), and p5-f (5′-[GC]50CTGGGGGTTCC-
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Figure 1 Strategy used to screen for MEFV-gene mutations with one representative DGGE experiment. a, Screening strategy. The strategy
includes restriction-enzyme analysis of PCR-amplified fragments, which was first performed to screen for the M694V and V726A mutations
(see Patients and Methods section). In the absence of these mutations, a DGGE-based screening system was performed to analyze 212 nucleotides
of exon 10 (fragment 10A) surrounding the four initially described mutations (i.e., M694V, V726A, M680I, and M694I); to further analyze
the MEFV gene, two DGGE experiments were performed to screen for sequence variations in the 3′ end of exon 10 (fragment 10B) and the
entire exon 5 together with flanking intronic sequences; the E148Q mutation was screened for by restriction-enzyme analysis; all the remaining
coding sequences and intronic boundaries were subsequently scanned for mutations by means of DGGE analysis. b, Representative DGGE
migration patterns of 10A PCR-amplified fragment of exon 10 from patients presenting with various genotypes. H  homoduplexes; h 
heteroduplexes. The asterisk (*) refers to the particular situation in which the PCR products did not display a shift in mobility; they thus were
systematically mixed with a PCR product from a normal control (v/v) and then were subjected to a cycle of melting and reassociating to generate
heteroduplexes that, in this case, point to the presence of the M680I mutation.
TGGACATCC-3′) and p5-r (5′-GAGCTGGGAGCC-
TGAGGCAT-3′), respectively. Fifteen microliters of the
PCR products were subjected to electrophoresis at 230
V during 5 h in a 6.5% polyacrylamide gel containing
a linearly increasing denaturing gradient (range
20%–70% [for fragments 10A and 10B] or 20%–80%
[for exon 5]). The FMF alleles that remained unchar-
acterized were subsequently screened for mutations in
all other MEFV coding exons and flanking splice junc-
tions (i.e., exons 1–4 and 6–9 and the 5′ part of exon
10), by means of DGGE, with experimental conditions
that are available on request. The PCR products that
did not display a shift in mobility were systematically
mixed with a PCR product from a normal control (v/v)
and were subjected to a cycle of melting and reasso-
ciating, to generate heteroduplexes, in order to improve
the sensitivity of the DGGE assay. All samples displaying
a shift in mobility were subsequently directly sequenced.
MEFV-Genotype Determination
The MEFV genotype of each affected individual car-
rying at least two different mutations was accurately
identified by different means, depending on both the
availability of parental DNA samples and the location
and nature of the two MEFV mutations. When DNA
samples from relatives were not available for study, we
analyzed the PCR products spanning the two identified
mutations, using the following procedures: determina-
tion of the genotype of patients who carried the M694V
and V726A mutations was performed by means of
DGGE analysis of fragment 10A, as described above (the
two mutated homoduplexes migrate at positions differ-
ent from that of the wild-type sequence); since the
M680I mutation resulted in homoduplexes that could
not be discriminated from wild-type homoduplexes (i.e.,
isostable mutation), the genotype of patients who carried
both the M680I and M694V mutations was accurately
identified by means of a double digestion of the PCR
products generated, by primers p10A-f and pM694V-r
(5′-GCTGGACGCCTGGTACTCATTTTCGTTAA-3′),
with restriction enzymes HpaI and HinfI; a similar ap-
proach was designed to accurately identify the genotype
of patients carrying the V726A and M680I mutations,
by use of primers pM680I-f (5′-GACATCCATA-
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Table 1
MEFV Gene–Sequence Variations in Armenian Patients
A. Spectrum of MEFV-Gene Mutations
Mutation No (%) of Independent Alleles
M694V 72–74 (44.8)a
V726A 39 or 40 (24.2)a
M680I 30 or 31 (18.7)a
F479L 4 (2.5)
E148Q 2 (1.2)
R761H 1 (.6)
E148Q-P369S-R408Qb 1 (.6)
Unidentified allele 12 (7.4)
Total 163 (100)
B. MEFV Gene Polymorphisms
Nucleotide Variantc Codon Location
306, TrC 102 Exon 2
414, ArG 138 Exon 2
495, CrA 165 Exon 2
605, GrA 202 Exon 2
942, CrT 314 Exon 3
135644, ArG ) Intron 4
1422, GrAd 474 Exon 5
1428, ArGd 476 Exon 5
1503, CrT 501 Exon 5
1518, CrT 506 Exon 5
1530, TrCd 510 Exon 5
158869, GrA ) Intron 5
17598, CrT ) Intron 8
176030, TrA ) Intron 8
1764, GrA 588 Exon 9
a In two independent patients, it was impossible to de-
termine which FMF allele (M694V or V726A in one pa-
tient and M694V or M680I in the other patient) was in-
herited from the affected parent.
b Identified in cis.
c Newly identified variations are underlined.
d Always associated in cis.
Table 2
Genotypes at the MEFV Locus in Armenian Patients
Genotype No (%)
M694V/M694V 18 (21.2)
M694V/V726A 22 (25.9)
M694V/M680I 13 (15.3)
V726A/M680I 9 (10.6)
M680I/M680I 4 (4.7)
V726A/V726A 3 (3.5)
V726A/F479L 3 (3.5)
M694V/E148Q 2 (2.4)
M680I/R761H 1 (1.2)
M680I/F479L 1 (1.2)
M680I/unidentified allele 1 (1.2)
M694V/unidentified allele 2 (2.4)
V726A/unidentified allele 2 (2.4)
E148Q-P369S-R408Qa/unidentified allele 1 (1.2)
Unidentified allele/unidentified allele 3 (3.5)
Total 85b(100)
a E148Q, P369S, and R408Q were associated in cis.
b Includes 77 independent patients and 8 patients
who shared one allele with an affected relative.
AGCAGGAAAGGGAAGAT-3′) and p10A-r, with re-
striction enzymes AluI and DpnII; primers p10C-f (5′-
GAGGTGGAGGTTGGAGACAA-3′) and p10B-r were
used to determine whether the M680I and R761H mu-
tations were located on the same allele or on two dif-
ferent MEFV alleles; in the latter case, the PCR products
were analyzed by enzymatic digestion by restriction en-
zyme NlaIII. pM694V-r and pM680I-f are mismatched
primers that allow enzymatic identification of the
M694V and M680I mutations, respectively. To precisely
determine the genotype of the patient who carried three
different MEFV mutations, we cloned the PCR fragment
generated by primers p2-f and p4-r (5′-CGGGGAC-
CCCTGCTCACT-3′), which encompasses the three mu-
tated sites.
Statistical Analysis
The statistical significance of differences between
groups was calculated by either the x2 test or Fisher’s
exact test. All statistical tests were two-sided.
Results
Characterization of Sequence Variations in the MEFV
Gene: Diagnostic Value of MEFV-Gene Analysis
By means of the strategy described in figure 1a, 23
different sequence variations were identified in our pop-
ulation sample. Seven of them (listed in table 1A) consist
of seven mutations—M694V, V726A, M680I, R761H,
F479L, E148Q, and P369S—that have been described
elsewhere (French FMF Consortium 1997; International
FMF Consortium 1997; Bernot et al. 1998; Cazeneuve
et al. 1998; Samuels et al. 1998; Aksentijevich et al.
1999), whereas one, R408Q (GrA transition at nucle-
otide 1223), is new and was found to be associated with
the E148Q and P369S mutations in the same patient.
The 15 remaining sequence variations, 5 of which are
new, are polymorphisms (i.e., silent substitutions or in-
tronic sequence variations) (table 1B). A representative
DGGE experiment illustrating the characterization of
different FMF alleles is shown in figure 1b.
The MEFV genotype of each individual carrying at
least two different mutations was accurately identified
by different means, depending on the availability of pa-
rental DNA samples and the location and nature of
MEFV mutations (see Patients and Methods section).
This analysis showed that, in our population of patients,
the eight identified missense mutations accounted for
93% of the 163 independent FMF alleles, with the
M694V substitution representing nearly half of the char-
acterized alleles (table 1A). Fourteen different genotypes
were characterized among 85 of the 90 patients (table
2); the 85 patients included 77 independent patients and
8 patients who shared one allele with an affected relative,
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Table 3
Clinical Features of FMF Patients with One or Two Uncharacterized FMF Alleles
PATIENT GENOTYPE
CLINICAL FEATURESa
Renal
Amyloidosis Arthritis Fever Peritonitis Pleurisy
Erysipelas-
like Rash Diarrhea
1 Unidentified allele/unidentified allele       
2 Unidentified allele/unidentified allele       
3 Unidentified allele/unidentified allele       
4 M694V/unidentified allele       
5 M694V/unidentified allele       
6 M680I/unidentified allele       
7 M680I/unidentified allele       Not available
8 V726A/unidentified allele       
9 Complex alleleb/unidentified allele       
a For each patient, recurrent attacks (i.e., at least three of the same type) associating at least two of the major established clinical criteria
(Livneh et al. 1997) were documented; the presence or absence of each clinical sign is indicated by a plus sign () or a minus sign (),
respectively.
b E148Q, P369S, and R408Q mutations in cis.
Figure 2 Pedigrees illustrating atypical modes of inheritance in
FMF. Pseudodominant transmission of the FMF phenotype is shown
in pedigrees a–c. Incomplete penetrance of the disease phenotype is
shown in pedigrees c–e (individuals CI2, DI1, and EII1, each of whom
carried two mutated MEFV alleles, are clinically asymptomatic). Note
the presence of both pseudodominant transmission and incomplete
penetrance in family c. The DNA samples from individuals AI1 and
BI2 were not available for study.
whereas the 5 remaining patients belonged to families
with affected siblings carrying identical MEFV geno-
types. The determination of the genotype in individuals
with at least two different MEFV mutations revealed
that all patients with two mutations were indeed com-
pound heterozygotes, whereas the patient with three mu-
tations (E148Q, P369S, and R408Q) actually carried all
three mutations in cis on the same allele (tables 1A and
2). The M694V homozygous and compound heterozy-
gous (M694V/other mutation) genotypes were displayed
by almost two-thirds of the patients. In this mutation-
screening procedure, both FMF alleles were character-
ized in 76 (89%) of the 85 patients. After a complete
screening for mutations of all MEFV coding exons and
intronic boundaries by means of DGGE, the two FMF
alleles remained unidentified in three patients, whereas
one FMF allele was uncharacterized in six patients (table
2); the disease features of these nine patients are pre-
sented in table 3. In addition, in three families, pseu-
dodominant transmission was clearly demonstrated,
with the patient’s affected parent carrying two mutated
MEFV alleles (fig. 2a–c).
Surprisingly, three healthy relatives of affected chil-
dren from three different families, who were investigated
within the framework of a systematic analysis, were
found to carry two mutated MEFV alleles: two of these
healthy relatives—one mother (individual CI2, age 51
years) and one father (individual DI1, age 46 years) of
affected children—displayed the V726A/M680I com-
pound-heterozygous genotype, whereas the remaining
healthy female relative (individual EII1, age 9 years) dis-
played the M694V/M680I compound-heterozygous ge-
notype (fig. 2c–e).
Phenotype-Genotype Correlations: Prognostic Value of
MEFV-Gene Analysis
To determine whether the clinical severity of the dis-
ease correlated with the MEFV genotype, we compared
the clinical features among subgroups of patients with
the three major genotypes (i.e., M694V homozygous,
M694V/V726A compound heterozygous, and M694V/
M680I compound heterozygous), as well as in M694V
homozygous patients versus patients with other geno-
types. Results of phenotype-genotype correlations are
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Table 4
Clinical Features Associated with MEFV Mutations in Armenian Patients with FMF
GENOTYPE
RENAL
AMYLOIDOSISa
(48.5%b) ARTHRITIS (60%b) FEVER (91%b)
PERITONITIS
(90%b) PLEURISY (57%b)
ERYSIPELAS-LIKE
RASH
(11.5%b)
DIARRHEA
(19%b)
Frequency P Frequency P Frequency P Frequency P Frequency P Frequency P Frequency P
M694V/M694V 10/10 18/21 20/21 19/21 9/20 4/20 4/19
M694V/V726A 1/8 12/24 20/24 22/24 18/23 1/24 2/24
M694V/M690I 2/4 7/13 13/13 13/13 8/13 1/13 2/11
Overallc .0009d .009d 1.05 1.05 1.05 1.05 1.05
M694V/M694V 10/10 18/21 20/21 19/21 9/20 4/10 4/19
Other 6/23 36/69 62/69 62/69 41/68 6/68 11/60
Overalle .0002 .006 1.05 1.05 1.05 1.05 1.05
a Both all the patients with renal amyloidosis and all the patients without amyloidosis who had not undergone colchicine therapy at age !40 years have been
taken into account.
b Overall frequency.
c P values apply to all three genotypes, unless otherwise indicated.
d Patients with the M694V/V726A and the M694V/M680I genotypes were grouped for this calculation.
e P values apply to the two genotypes.
Table 5
Point Prevalence of Renal Amyloidosis, According to
Genotypes at the MEFV Locus
Genotype Prevalencea
M694V/M694V 10/10
M694V/V726A 1/ 8
M694V/M680I 2/ 4
V726A/M680I 2/ 3
V726A/V726A 1/ 3
M680I/R761H 0/ 1
M694V/unidentified allele 0/ 2
M680I/unidentified allele 0/ 1
E148Q-P369S-R408Qb/unidentified allele 0/ 1
Total 16/33
a All the patients presenting with renal amyloidosis
have been taken into account, as have those without amy-
loidosis who had not undergone colchicine therapy at
age !40 years (see text).
b The E148Q, P369S, and R408Q mutations were as-
sociated in cis.
summarized in table 4. In addition, to identify the clin-
ical signs associated with each FMF mutation, pheno-
type-genotype correlations between the groups of pa-
tients with one or two M694V, V726A, or M680I alleles
and the group of patients who did not carry the partic-
ular mutation were also studied.
The prevalence of renal amyloidosis was assessed by
taking into account both (a) all the patients with renal
amyloidosis and (b) those without renal amyloidosis
who had not undergone colchicine therapy at age !40
years, since amyloidosis usually appears at age !40 years
(Sohar et al. 1967) (table 5). MEFV-gene analysis re-
vealed that renal amyloidosis was not observed in the
three patients who had one or two uncharacterized al-
leles (table 5). We found a higher point prevalence of
renal amyloidosis in M694V homozygous patients than
in patients with other genotypes (10/10 vs. 6/23 [P 
]); the difference was also significant when M694V.0002
homozygous patients were compared with M694V/
V726A compound-heterozygous patients (10/10 vs. 1/8
[ ]). However, there was no significant varia-P  .0005
tion, in terms of the point prevalence of renal amyloi-
dosis, when patients bearing one or two M694V alleles
were compared with patients who did not carry the
M694V allele; the same conclusion was obtained both
(a) when patients with one or two V726A alleles were
compared with patients who did not carry the V726A
mutation and (b) when patients with one or two M680I
alleles were compared with patients who did not carry
the M680I mutation (data not shown).
The M694V homozygous patients also presented
more frequently with arthritis, compared with patients
who had other genotypes ( ); the difference wasP  .006
also significant when M694V homozygous patients were
compared with patients carrying the two other major
genotypes (i.e., M694V/V726A and M694V/M680I)
( ) (table 4). With regard to the prevalence ofP  .009
either fever, peritonitis, pleurisy, erysipelas-like rash, or
diarrhea, there was no significant difference either be-
tween the M694V homozygous, the M694V/V726A
compound-heterozygous, and the M694V/M680I com-
pound-heterozygous subgroups of patients (table 4) or
in patients with one or two M694V, V726A, or M680I
alleles versus patients who did not have the particular
mutation (data not shown).
Discussion
We tested the diagnostic value of MEFV-gene analysis
in FMF patients belonging to a population that displayed
several important characteristics: the studied population
consisted of a large number of independent families;
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none of these families were selected through linkage
analyses using MEFV-gene markers; rather, all the pa-
tients were included in this study solely because they
fulfilled the established clinical criteria for the diagnosis
of FMF. Delineation of the spectrum of MEFV mutations
in our cohort of Armenian patients led to the identifi-
cation of (a) three mutations (i.e., M694V, V726A, and
M680I) of the four located in exon 10 that were initially
reported (French FMF Consortium 1997; International
FMF Consortium 1997); (b) the more recently reported
mutations—E148Q, F479L, and R761H, located in ex-
ons 2, 5 and 10, respectively (Bernot et al. 1998); and
(c) the P369S mutation, located in exon 3 (Aksentijevich
et al. 1999). The R408Q mutation, which was identified
in the present study, was present on only one FMF allele.
Although the functional significance of this mutation
remains to be demonstrated, it is noteworthy that the
substitution replaces a charged residue by a neutral
amino acid; in addition, this nonconservative mutation
lies in a region that comprises the C-terminal residues
of the evolutionarily conserved B-box zinc-finger domain
potentially involved in protein-protein interactions
(Reddy et al. 1992); furthermore, when compared with
residues occupying the same position in other members
of the B-box family, Arg408 follows His407, which be-
longs to the conserved His/Cys residues potentially in-
volved in metal binding. Nevertheless, residue 408 is not
evolutionarily conserved: several members of the B-box
family, including MID1, a putative transcription factor
mutated in Opitz G/BBB syndrome (Quaderi et al. 1997),
Staf50, an interferon-induced protein (Tissot and Mechti
1995), and rpt-1, a protein involved in the down-reg-
ulation of the interleukin-2 receptor (Partaca et al.
1988), contain a glutamine residue at this position; how-
ever, this striking observation is not sufficient to exclude
any pathological consequences of the R408Q mutation,
since a similar situation exists for the M680I, V726A,
and R761H mutations located in another evolutionarily
conserved domain of the protein, the B30.2 domain.
Molecular tools, which were developed to screen all
MEFV coding exons and flanking intronic boundaries
for mutations, represent the first laboratory tests of di-
agnostic value for the disease, with the eight identified
mutations accounting for 93% of the 163 independent
FMF alleles and with both FMF alleles being character-
ized in 89% of our patients. Such a diagnostic value of
MEFV-gene analysis was not documented in a recent
study performed in a non-Ashkenazi Jewish population
of patients (Eisenberg et al. 1998); however, the differ-
ence between the latter study—which was designed to
search for only three MEFV mutations in a smaller pop-
ulation of independent patients—and our study may re-
sult from MEFV allelic differences between two popu-
lations that do not share the same genetic background.
In light of our results, in the Armenian population, it is,
in return, now conceivable to design prospective studies
to accurately evaluate the different sets of clinical criteria
for the diagnosis of FMF (Livneh et al. 1997), by use of
the result of MEFV-gene analysis as the first objective
diagnostic criterion. By use of this molecularly based
diagnostic procedure, one FMF allele remained unchar-
acterized in only six patients, and no mutation was de-
tected in three patients, even after the screening of all
MEFV coding regions and intronic boundaries. Several
hypotheses may account for these observations: (i) in
these patients, sequence variations may exist in the unex-
plored regions of the MEFV gene (i.e., intronic se-
quences, promoter and untranslated regions); (ii) al-
though it is clearly established that DGGE is a highly
sensitive technique for mutation detection (Cotton
1997), we cannot rule out the possibility that, in rare
instances, a few mutations remained undetected by this
experimental procedure; (iii) given the absence of any
objective criterion for the diagnosis of FMF, the FMF-
like symptomatology presented by these patients may
result from a different disease, although, in these nine
patients, the clinical diagnosis was still clear in retro-
spect. However, FMF shares several clinical features with
other periodic-fever syndromes, such as hyperimmunog-
lobulinemia D with periodic-fever syndrome (MIM
260920) and dominantly inherited familial Hibernian
fever (MIM 142680). Although, so far, these periodic-
fever syndromes have not been reported in patients of
Armenian ancestry, we can anticipate that, in this pop-
ulation, MEFV mutation analysis would be helpful for
differential diagnosis of these clinically related
syndromes.
One striking feature of FMF is the recent description
of complex alleles with two mutations associated in
cis—that is, alleles E148Q-I692del and E167D-F479L
(Bernot et al. 1998), E148Q-V726A (Bernot et al. 1998;
Aksentijevich et al. 1999), and E148Q-P369S (Aksen-
tijevich et al. 1999). In this study, we identified the first
FMF allele containing three different mutations in cis:
E148Q-P369S-R408Q, the R408Q mutation having not
been previously identified on other P369S or E148Q
alleles, an observation that further documents the mo-
lecular diversity of the complex alleles found in FMF. In
theory, such alleles could arise either sequentially, by the
occurrence of independent mutational events, or by in-
tragenic recombinations between simple alleles; in FMF,
MEFV haplotype analyses rather favor the latter hy-
pothesis (Bernot et al. 1998; Aksentijevich et al. 1999).
The description of complex alleles may also have im-
portant clinical consequences: this unusual feature raises
the question as to the extend to which the MEFV-gene
analysis should be completed when two different mu-
tations have been identified (i.e., are the two mutations
located on the same allele? do other mutations exist in
the same gene?). In addition, in the absence of functional
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studies, one cannot exclude the possibility that some of
the mutations identified in complex alleles either produce
a mild effect or are simple polymorphisms; this could
especially be the case for the E148Q and/or P369S mu-
tations, which, in several instances, have been found in
association with other mutations (Bernot et al. 1998;
Aksentijevich et al. 1999; present study); this may also
account for the high carrier frequency with reduced pen-
etrance just recently reported for E148Q and P369S in
the Ashkenazi Jewish population (Aksentijevich et al.
1999).
In the course of our study, in three unrelated families
three healthy relatives (one male and two females) of
affected children were found to carry two mutated
MEFV alleles. These observations, which were docu-
mented with likely disease-causing mutations (i.e.,
V726A and M680I) in two adults, provide molecular
evidence for incomplete penetrance of the disease phe-
notype and point out the likely existence of modifier
factors; in the healthy 9-year-old girl with the M694V/
M680I genotype, a delayed onset of the disease cannot
be ruled out, although her brother, who carries the same
genotype, has exhibited typical FMF disease since age 3
years. One part of the modifier factors may be related
to sex; this is indeed suggested by the unbalanced male:
female ratio (1.20:1.00) in our population of patients,
an observation that already has been reported by others
(Saatci et al. 1997) and that, in theory, may result from
the incomplete penetrance of the disease phenotype in
females and/or an increased embryonic death of female
zygotes with two mutated MEFV alleles.
In three families, MEFV-gene analysis showed that the
parent-to-offspring transmission of the disease pheno-
type was explained by the presence of two mutated
MEFV alleles in the affected parent. These molecular
data, which further clarify the atypical mode of inher-
itance reported by others (Rogers et al. 1989; Yuval et
al. 1995), demonstrate a pseudodominant transmission
of the disease. Pseudodominant transmission and incom-
plete penetrance of the disease phenotype should, there-
fore, be taken into account when FMF families are in-
vestigated within the framework of molecular diagnosis;
in addition, as shown in this study (fig. 2c), the mode
of inheritance of the disease phenotype can be further
complicated by the association of both pseudodominant
transmission and incomplete penetrance within the same
nuclear family.
To interpret the correlation data that we observed be-
tween the genotype and the clinical symptomatology, it
is important to emphasize that all investigated patients
were of Armenian ancestry; they were therefore expected
to share a common genetic background, thereby allow-
ing correlation studies in a relatively homogeneous pop-
ulation; in addition, the occurrence of renal amyloidosis,
which is a long-term complication of the disease, could
not have been prevented in the patients who did not
have access to daily administration of colchicine. When
both all the patients with amyloidosis and those without
amyloidosis who had not undergone colchicine therapy
at age !40 years were considered, the prevalence of renal
amyloidosis was 16/33 (48.5%); the high rate of this
renal complication, which was observed only in patients
who had not undergone regular colchicine therapy, fur-
ther underscores the critical importance of the treatment
(Zemer et al. 1986).
One of the most striking results of this study is the
strongly unfavorable prognostic value that the M694V
homozygous genotype has with respect to renal function.
The prevalence of renal amyloidosis is indeed higher in
M694V homozygous patients than in patients with other
MEFV genotypes ( ). This statistically signifi-P  .0002
cant association of the M694V homozygous genotype
with renal amyloidosis was not shown in the recent stud-
ies that investigated populations of patients who either
had been undergoing colchicine therapy for many years
(Dewalle et al. 1998; Samuels et al. 1998) or were ge-
netically heterogeneous with a limited number of pa-
tients carrying the M694V homozygous genotype (Sa-
muels et al. 1998). In other respects, no significant
difference in the frequency of amyloidosis was observed
in our patients carrying one or two M694V alleles versus
patients who did not carry the M694V mutation; similar
results were obtained with the V726A or M680I mu-
tation. The presence of two M694V alleles was, there-
fore, associated with a higher severity of the disease, as
judged by the higher prevalence of this major compli-
cation, as well as by the higher frequency of arthritis
( ). It is also striking to note that renal amyloi-P  .006
dosis was absent in the three patients who had not un-
dergone colchicine therapy at age !40 years and who
had one or two uncharacterized FMF alleles; the study
of a larger cohort of patients would be decisive in dem-
onstrating whether the presence of, at most, one of the
MEFV mutations recovered in the present study is a
favorable prognostic factor. Taken together, such a di-
agnostic and prognostic value of MEFV-gene analysis
also further confirms the involvement of the MEFV gene
in FMF.
The availability of a molecularly based FMF diag-
nosis, the clear-cut demonstration of both the incomplete
penetrance and the pseudodominance of the disease phe-
notype, and the prognostic value of MEFV-gene analysis
have several major clinical implications: MEFV-gene
analysis performed within the framework of genetic
counseling may accurately identify affected individuals
as early as the first attack, thereby not only providing
the possibility to start colchicine therapy precociously
but also preventing unnecessary investigations, including
invasive procedures such as laparotomies. In addition,
MEFV genotyping may also identify individuals in their
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presymptomatic phase, raising the pertinence of starting
a prophylactic colchicine therapy. However, a propor-
tion of these individuals with two mutated MEFV al-
leles—a proportion that has to be determined in a large
cohort of healthy relatives of FMF patients—will never
present with FMF symptoms. In other respects, one
should also keep in mind the report of renal amyloidosis
in FMF patients without attacks of serositis (Blum et al.
1962; Sohar et al. 1967; Saatci et al. 1997); at first
glance, this observation might encourage colchicine ther-
apy in asymptomatic individuals with two MEFV mu-
tations, especially if they carry the M694V homozygous
genotype, which is strongly associated with renal amy-
loidosis. Although it is clear that the molecular inves-
tigations performed in FMF families will therefore lead
to new ways of managing the disease, large population-
based screening studies will be necessary to define the
best therapeutic attitude to adopt in each affected family.
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